Neutropenia
Edinburgh Cancer Centre (intranet): G-CSF Guideline NHS Lothian (intranet): G-CSF Haematology Policy
Treatment of neutropenia
Filgrastim
Filgrastim 30million units/0.5ml solution for injection pre-filled syringes
Dose as per specialist.
Filgrastim 48million units/0.5ml solution for injection pre-filled syringes
Dose as per specialist.
Lenograstim
Lenograstim 13.4million unit powder and solvent for solution for injection pre-filled syringes
Dose as per specialist.
Lenograstim 33.6million unit powder and solvent for solution for injection pre-filled syringes
Dose as per specialist.
Pegfilgrastim and lipegfilgrastim are long-acting g-CSF formulations.
Pegfilgrastim
Pegfilgrastim 6mg/0.6ml solution for injection pre-filled syringes
Dose as per specialist.
Pegfilgrastim 6mg/0.6ml solution for injection pre-filled disposable devices
Dose as per specialist.
Lipegfilgrastim
Lipegfilgrastim 6mg/0.6ml solution for injection pre-filled syringes
Dose as per specialist.
Prescribing Notes:
- A long-acting g-CSF formulation (e.g pegfilgrastim or lipegfilgrastim) may be used only in patients who are physically unable to self-inject daily filgrastim, or do not have a carer who can do this for them, or have a clinical issue which precludes use of daily filgrastim.
- For regimens where there is <12 days between SACT dose, use of long acting GCSF is contraindicated.
- Due to potential risk of lung hyperinflammation in patients diagnosed with COVID-19, GCSF should be stopped if a patient on GCSF treatment is admitted with signs of sepsis, lung inflammation and potential COVID -19. GCSF treatment should be withheld until a negative swab is obtained or lungs are deemed unaffected.
History Notes
20/04/2023
East Region Formulary content agreed.
Treatment of neutropenia
Lenograstim
Lenograstim 13.4million unit powder and solvent for solution for injection pre-filled syringes
See product literature.
Lenograstim 33.6million unit powder and solvent for solution for injection pre-filled syringes
See product literature.
Prescribing Notes:
- Granocyte solution for injection contains 105 micrograms of lenograstim per 13.4 million unit vial and 263 micrograms lenograstim per 33.6 million unit vial.
History Notes
10/06/2020
Content migrated from LJF website.